Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Employees - 30,
CEO - Dr. Maria Palasis Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 6.38M
Altman ZScore(max is 10): -12.42, Piotroski Score(max is 10): 3, Working Capital: $22435000, Total Assets: $56316000, Retained Earnings: $-413337000, EBIT: -46178000, Total Liabilities: $52444000, Revenue: $1185000
- Current Price $0.10 - Analyst Target Price $2.00| Ticker | LYRA |
| Index | RUT |
| Curent Price | 0.10 |
| Change | -9.82% |
| Market Cap | 6.38M |
| Average Volume | 3.23M |
| Income | -79.53M |
| Sales | 1.19M |
| Book Value/Share | 0.06 |
| Cash/Share | 0.48 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 30 |
| Moving Avg 20days | -7.50% |
| Moving Avg 50days | -20.05% |
| Moving Avg 200days | -52.85% |
| Shares Outstanding | 65.88M |
| Earnings Date | May 06 AMC |
| Inst. Ownership | 36.55% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 5.37 |
| Price/Book | 1.64 |
| Price/Cash | 0.20 |
| Price/FCF | - |
| Quick Ratio | 2.96 |
| Current Ratio | 2.96 |
| Debt/Equity | 8.62 |
| Return on Assets | -80.40% |
| Return on Equity | -195.46% |
| Return on Investment | -241.11% |
| Gross Margin | 60.93% |
| Ops Margin | -3811.39% |
| Profit Margin | -6711.39% |
| RSI | 42.28 |
| BETA(β) | 0.01 |
| From 52week Low | 17.56% |
| From 52week High | -75.90% |
| EPS | -1.21 |
| EPS next Year | -0.66 |
| EPS next Qtr | -0.14 |
| EPS this Year | 55.94% |
| EPS next 5 Year | 21.95% |
| EPS past 5 Year | -2.22% |
| Sales past 5 Year | 78.20% |
| EPS Y/Y | 2.71% |
| Sales Y/Y | -29.46% |
| EPS Q/Q | 62.94% |
| Sales Q/Q | -65.60% |
| Sales Surprise | -23.75% |
| EPS Surprise | 13.33% |
| ATR(14) | 0.02 |
| Perf Week | 2.12% |
| Perf Month | 10.42% |
| Perf Quarter | -51.17% |
| Perf Year | -73.78% |
| Perf YTD | -53.29% |
| Target Price | 2.00 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer